Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Biochemistry

Background:

• The innate immune system's role in multiple sclerosis (MS) is gaining attention.
• Acute inflammatory mediators are implicated in MS pathogenesis.

Purpose of the Study:

• To investigate the involvement of systemic secreted phospholipase A2 (sPLA2) enzymes in experimental autoimmune encephalomyelitis (EAE), a model for MS.
• To determine if sPLA2 enzyme activity is elevated in MS patients.

Main Methods:

• Developed a non-invasive urinary assay to monitor active sPLA2 levels in EAE rats.
• Administered CHEC-9, an sPLA2 inhibitor, to rats and monitored EAE clinical scores and histopathology.
• Assessed urinary sPLA2 levels in MS patients and healthy controls.

Main Results:

• Urinary sPLA2 levels peaked before EAE onset in rats.
• CHEC-9 treatment reduced EAE symptoms and spinal cord inflammation.
• MS patients, both with active disease and in remission, exhibited elevated urinary sPLA2 activity.

Conclusions:

• sPLA2 enzymes, linked to acute inflammation, represent potential therapeutic targets for MS.
• Targeting sPLA2 may offer a novel treatment strategy for multiple sclerosis.